Caris Life Sciences, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2020 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 294.01M | 258.49M | 306.13M | 412.26M | 812.03M | 97.0% | |
| Cost of Revenue | (109.86M) | (178.46M) | (216.82M) | (233.48M) | (272.87M) | 16.9% | |
Gross Profit | 184.16M | 80.02M | 89.31M | 178.78M | 539.17M | 201.6% | |
| Operating Expenses | |||||||
| Research & Development | — | (101.27M) | (116.88M) | (113.92M) | (45.31M) | -60.2% | |
| Selling, General & Administrative | (27.31M) | (294.51M) | (291.48M) | (321.86M) | (392.47M) | 21.9% | |
| General & Administrative | (27.31M) | (156.15M) | (151.95M) | (173.56M) | (224.97M) | 29.6% | |
| Selling & Marketing | — | (138.36M) | (139.53M) | (148.30M) | (167.51M) | 13.0% | |
| Depreciation & Amortization | (110.65M) | (48.25M) | (49.00M) | (48.91M) | (22.61M) | -53.8% | |
Operating Income (EBIT) | 139.09M | -315.76M | -319.55M | -257.12M | 45.11M | -117.5% | |
| Non-Operating Items | |||||||
| Interest Income | — | 947.00K | 11.26M | 7.12M | 16.50M | 131.6% | |
| Interest Expense | (61.56M) | (26.68M) | (31.61M) | (50.02M) | (56.85M) | 13.6% | |
| Other Income/Expenses (Net) | -109.55M | -5.07M | -21.86M | -24.77M | -113.20M | 357.0% | |
Income Before Tax | 29.53M | -320.83M | -341.42M | -281.89M | -68.09M | -75.8% | |
| Income Tax Expense | (1.80M) | — | — | — | (469.87M) | — | |
Net Income | 27.73M | -320.83M | -341.42M | -281.89M | -537.96M | 90.8% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $-2 | $-2 | $-3 | $-2 | -29.3% | |
| Weighted Avg Shares Outstanding | 17.95M | 254.79M | 254.66M | 254.66M | 282.33M | 10.9% | |
| Weighted Avg Shares Outstanding (Diluted) | 17.95M | 254.79M | 254.66M | 254.66M | 289.89M | 13.8% | |
EBITDA | 254.46M | -245.89M | -260.80M | -182.95M | 11.38M | -106.2% |
Explore CAI
CAI in the Healthcare
Mid Cap